Answers are grounded in this paper and cite their sources.
Matched-cohort study validates survival benefit of FLOT chemotherapy over CROSS in adenocarcinoma patients.
Background: The ESOPEC trial recently demonstrated a survival advantage of perioperative FLOT chemotherapy over neoadjuvant CROSS chemoradiation in patients with resectable esophageal and gastroesophageal junction adenocarcinoma. To validate these findings in a real-world setting, we conducted a population-based analysis using by the German Cancer Registry Group of the Society of German Tumor Centers ([Table 1]).
No takes yet. Share an insight, caveat, or question.
Abdalla et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: